Home › Trials › NCT06171139
Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

Counseling tool for Black men with metastatic prostate cancer

Official title: Developing and Testing a Patient-centered Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Metastatic Prostate Cancer

Run by University of California, San Francisco · NCT06171139 · Data updated 2026-11-12

This study tests a new counseling tool to see if it helps Black men with metastatic prostate cancer understand genetic testing better and if they find it useful.

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment80 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedDecember 1, 2023
Main results expectedMay 31, 2027
Study endsAugust 31, 2027
Registry record updatedApril 16, 2026
Trial IDNCT06171139 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are Black or African American men aged 18 and older who have metastatic prostate cancer and are considering or have declined tumor genetic testing.

Probably not a fit

Patients who do not identify as Black or African American or those without metastatic prostate cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the equitable delivery of a pre-tumor genetic testing counseling tool specifically designed for Black or African American men diagnosed with metastatic prostate cancer. It consists of two stages: the first evaluates the educational quality and content completeness of the intervention, while the second assesses its feasibility and acceptability among participants. Participants will engage with the counseling tool and provide feedback through questionnaires over a period of up to 60 days.

Why it matters

Potential benefit: If successful, this study could improve access to and understanding of tumor genetic testing for Black or African American men with metastatic prostate cancer.

How similar studies have gone: While there may be studies focusing on genetic testing in prostate cancer, this specific approach targeting Black or African American men is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Stage 1:

1. Age 18-years-old or older
2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race, including Black or African American, is included.
3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
4. Able to understand study procedures and to comply with them for the entire length of the study.
5. Able to understand a written information sheet and willing to verbally consent.
6. Fluent in English (reading, writing, and speaking)

Stage 2:

1. Age 18-years-old or older
2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race, including Black or African American, is included.
3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
4. Able to understand study procedures and to comply with them for the entire length of the study.
5. Fluent in English (reading, writing, and speaking).
6. Anticipated discussion of TGT within 0-365 days of enrollment, per treating oncology provider's discretion. TGT involves the use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:

   1. Somatic DNA testing of already-collected tissue.
   2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
   3. Blood-based DNA testing to evaluate for circulating tumor DNA.
7. Able to understand a written informed consent document and willing to sign it.

Exclusion Criteria:

Contraindication to any study-related procedure or assessment in either stage.

Where it's running

  • University of California
    San Francisco, California, United States     Recruiting

Study contacts

  • Principal investigator: Daniel Kwon, MD — University of California, San Francisco
  • Study coordinator: Daniel Avins
  • Email: Daniel.Avins@ucsf.edu
  • Phone: 877-827-3222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Prostate Cancer Metastatic 26University of California, San Francisco 3127
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.